Case Report: Treatment of systemic mastocytosis with sunitinib.

The case report discusses the treatment of systemic mastocytosis, a rare variant of mast cell activation disease, with the tyrosine kinase inhibitor sunitinib. Typically, systemic mastocytosis is managed using therapies that target mast cell mediator production and action or inhibit cell proliferation. The study illustrates the potential application of sunitinib, a tyrosine kinase inhibitor, in treating cases of systemic mastocytosis that do not respond to the standard treatments used for this condition, such as those involving imatinib-resistant KIT mutations. This report suggests the importance of exploring and understanding alternative therapeutic options in managing complex mast cell disorders.